Damci, Taner <br/><br/>
Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.  [electronic resource] 

 -  Diabetes care  May 2004 
 - 1077-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0149-5992 
<br/><br/><label>Standard No.: </label>10.2337/diacare.27.5.1077  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anti-Obesity Agents--therapeutic use<br/>Cross-Over Studies<br/>Diabetes Mellitus--blood<br/>Diabetes Mellitus, Type 2--blood<br/>Female<br/>Gastric Inhibitory Polypeptide--blood<br/>Glucagon--blood<br/>Glucagon-Like Peptide 1<br/>Humans<br/>Insulin--blood<br/>Lactones--therapeutic use<br/>Male<br/>Middle Aged<br/>Obesity<br/>Orlistat<br/>Peptide Fragments--blood<br/>Protein Precursors--blood<br/>Single-Blind Method<br/>Weight Loss